A team of scientists from the University of Pittsburgh School Of Medicine has found the smallest molecule, which can specifically defuse SARS-CoV-2, which causes COVID19 infection. Experts have said that this antibody component is 10 times smaller than a full-fledged antibody, which has been used to develop a drug called Ab8. This drug is considered quite effective in preventing SARS-CoV-2. Experts have used this drug on mice and hamsters during the test to determine the efficacy of the medicine. Scientists inform that the drug does not attach to the human cell that means it will be a safe drug for people without any negative side effects. This study has been reported in the journal Cell.
The co-author of the research John Mellors has claimed that Ab8 is not only a potential therapy for COVID19 but it can also keep people safe from SARS-CoV-2 infection. Dr. John Mellors is the head of the Division of Infectious Diseases at the University of Pittsburgh Medical Center. He has said that antibodies of larger size work well on other infectious ailments, which paves the way for an effective treatment for patients with COVID19. He has claimed that this antibody will protect those people as well, who have never been infected with SARS-CoV-2 and do not have immunity against the virus. Experts have also been deciding on the administration of the drug. They have said that it can be given to people through a superficial injection instead of an IV injection. Experts have said the drug can be inhaled as well.
A team of scientists at the University of Texas Medical Branch Center For Biodefense, in association with Emerging Diseases and Galveston National Laboratory has analyzed the drug Ab8 thoroughly. The team has found that the drug has been able to prevent the virus from entering the cells. In the trial on mice, experts have found that those who have received treatment with Ab8 have shown 10 times less virus infection as compared to those who have not been given Ab8.